These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
424 related articles for article (PubMed ID: 27537991)
41. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. Beck LA; Thaçi D; Hamilton JD; Graham NM; Bieber T; Rocklin R; Ming JE; Ren H; Kao R; Simpson E; Ardeleanu M; Weinstein SP; Pirozzi G; Guttman-Yassky E; Suárez-Fariñas M; Hager MD; Stahl N; Yancopoulos GD; Radin AR N Engl J Med; 2014 Jul; 371(2):130-9. PubMed ID: 25006719 [TBL] [Abstract][Full Text] [Related]
42. Adverse events of Dupilumab in adults with moderate-to-severe atopic dermatitis: A meta-analysis. Ou Z; Chen C; Chen A; Yang Y; Zhou W Int Immunopharmacol; 2018 Jan; 54():303-310. PubMed ID: 29182975 [TBL] [Abstract][Full Text] [Related]
43. Dupilumab for the Treatment of Atopic Dermatitis. Ferreira S; Torres T Actas Dermosifiliogr (Engl Ed); 2018 Apr; 109(3):230-240. PubMed ID: 29422431 [TBL] [Abstract][Full Text] [Related]
44. Ameliorating effect of dipotassium glycyrrhizinate on an IL-4- and IL-13-induced atopic dermatitis-like skin-equivalent model. Lee SH; Bae IH; Choi H; Choi HW; Oh S; Marinho PA; Min DJ; Kim DY; Lee TR; Lee CS; Lee J Arch Dermatol Res; 2019 Mar; 311(2):131-140. PubMed ID: 30506356 [TBL] [Abstract][Full Text] [Related]
45. Relative efficacy of systemic treatments for atopic dermatitis. Seger EW; Wechter T; Strowd L; Feldman SR J Am Acad Dermatol; 2019 Feb; 80(2):411-416.e4. PubMed ID: 30296535 [TBL] [Abstract][Full Text] [Related]
47. Virus-Like Particle-Mediated Vaccination against Interleukin-13 May Harbour General Anti-Allergic Potential beyond Atopic Dermatitis. Foerster J; Molęda A Viruses; 2020 Apr; 12(4):. PubMed ID: 32294982 [TBL] [Abstract][Full Text] [Related]
48. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). de Bruin-Weller M; Thaçi D; Smith CH; Reich K; Cork MJ; Radin A; Zhang Q; Akinlade B; Gadkari A; Eckert L; Hultsch T; Chen Z; Pirozzi G; Graham NMH; Shumel B Br J Dermatol; 2018 May; 178(5):1083-1101. PubMed ID: 29193016 [TBL] [Abstract][Full Text] [Related]
49. Novel systemic therapies in atopic dermatitis: what do we need to fulfil the promise of a treatment revolution? Alexander H; Patton T; Jabbar-Lopez ZK; Manca A; Flohr C F1000Res; 2019; 8():. PubMed ID: 30774935 [TBL] [Abstract][Full Text] [Related]
50. Type 2 helper T-cell cytokines induce morphologic and molecular characteristics of atopic dermatitis in human skin equivalent. Kamsteeg M; Bergers M; de Boer R; Zeeuwen PL; Hato SV; Schalkwijk J; Tjabringa GS Am J Pathol; 2011 May; 178(5):2091-9. PubMed ID: 21514424 [TBL] [Abstract][Full Text] [Related]
51. Can we safely use systemic treatment in atopic dermatitis during the COVID-19 pandemic? Overview of selected conventional and biologic systemic therapies. Marko M; Pawliczak R Expert Rev Clin Immunol; 2021 Jun; 17(6):619-627. PubMed ID: 33866905 [No Abstract] [Full Text] [Related]
53. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE). Simpson EL; Flohr C; Eichenfield LF; Bieber T; Sofen H; Taïeb A; Owen R; Putnam W; Castro M; DeBusk K; Lin CY; Voulgari A; Yen K; Omachi TA J Am Acad Dermatol; 2018 May; 78(5):863-871.e11. PubMed ID: 29353026 [TBL] [Abstract][Full Text] [Related]
54. Interleukin antagonists for atopic dermatitis: a new era of therapy. Tsiogka A; Paschou E; Koumaki D; Vakirlis E; Gregoriou S Expert Opin Investig Drugs; 2024 Jun; 33(6):549-559. PubMed ID: 38656240 [TBL] [Abstract][Full Text] [Related]
55. [New aspects in systemic treatment of atopic dermatitis]. Werfel T; Wollenberg A; Pumnea T; Heratizadeh A Hautarzt; 2018 Mar; 69(3):217-224. PubMed ID: 29470609 [TBL] [Abstract][Full Text] [Related]
56. Diagnosis and Management of Conjunctivitis for the Dermatologist. Gooderham M; McDonald J; Papp K J Cutan Med Surg; 2018; 22(2):200-206. PubMed ID: 29191053 [TBL] [Abstract][Full Text] [Related]
57. Atopic dermatitis treatment: Current state of the art and emerging therapies. Silverberg JI Allergy Asthma Proc; 2017 Jul; 38(4):243-249. PubMed ID: 28668106 [TBL] [Abstract][Full Text] [Related]
58. Atopic dermatitis 2017: where we were 10-15 years ago in psoriasis. No DJ; Amin M; Egeberg A; Thyssen JP; Wu JJ J Dermatolog Treat; 2018 Feb; 29(1):100-101. PubMed ID: 28604121 [TBL] [Abstract][Full Text] [Related]
59. Commonality of the IL-4/IL-13 pathway in atopic diseases. Gandhi NA; Pirozzi G; Graham NMH Expert Rev Clin Immunol; 2017 May; 13(5):425-437. PubMed ID: 28277826 [TBL] [Abstract][Full Text] [Related]